Cadila Healthcare shares gained 4 percent after its group company entered into a sub-licensing agreement with The Medicines Patent Pool for hepatitis C medicine, daclatasvir. "Zydus Cadila has signed a non-exclusive, royalty free agreement with the The Medicines Patent Pool for the generic production of Bristol-Myers Squibb's daclatasvir," says the Ahmedabad-based pharma company in its filing. Daclatasvir, a direct-acting antiviral, is proven to help cure multiple genotyes of the hepatitis C virus. The agreement sub-licences Zydus to produce and sell daclatasvir in 112 low and middle income countries. The Medicines Patent Pool is a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. At 15:12 hours IST, the scrip of Cadila Healthcare was quoting at Rs 341.40, up Rs 6.75, or 2.02 percent amid high volumes on BSE.
Please visit SoulofHealing.org, non profit, 501(c)(3) for our patient assistance programs. If you have been denied by insurance or you do not have insurance please visit SunnyPharma.info to get generic Sovaldi($695), Harvoni($1495), Epclusa($2195) and Daklinza($695). All prices are based upon 12 weeks and 84 tablets. Verified by American doctors and nurses.
No comments:
Post a Comment